155 related articles for article (PubMed ID: 19487844)
21. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
22. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.
Weiler-Sagie M; Bushelev O; Epelbaum R; Dann EJ; Haim N; Avivi I; Ben-Barak A; Ben-Arie Y; Bar-Shalom R; Israel O
J Nucl Med; 2010 Jan; 51(1):25-30. PubMed ID: 20009002
[TBL] [Abstract][Full Text] [Related]
23. Tubercular Meningitis on 18F-FDG PET/CT: Incidentally Detected and Masquerading as Relapse in a Patient With Ovarian Burkitt Lymphoma.
Sharma P; Marangmei C
Clin Nucl Med; 2015 Jul; 40(7):606-7. PubMed ID: 25706796
[TBL] [Abstract][Full Text] [Related]
24. Burkitt lymphoma and cavernous sinus syndrome with breast uptake on 18F-FDG-PET/CT: A case report.
Reyneke F; Mokgoro N; Vorster M; Sathekge M
Medicine (Baltimore); 2017 Nov; 96(46):e8687. PubMed ID: 29145302
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT metabolic activity assessment in infective and neoplastic diseases: a patient with systemic hydatidosis and concomitant Burkitt lymphoma.
Niccoli Asabella A; Altini C; Pisani AR; Ingravallo G; Rubini G
Clin Nucl Med; 2013 Jul; 38(7):546-9. PubMed ID: 23640218
[TBL] [Abstract][Full Text] [Related]
26. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
[TBL] [Abstract][Full Text] [Related]
27. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
28. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
30. Characterization of T-cell lymphomas by FDG PET/CT.
Feeney J; Horwitz S; Gönen M; Schöder H
AJR Am J Roentgenol; 2010 Aug; 195(2):333-40. PubMed ID: 20651187
[TBL] [Abstract][Full Text] [Related]
31. Sporadic Burkitt Lymphoma Mimicking Osteomyelitis of the Mandible Revealing Clinically Unsuspected HIV Infection.
Sivolella S; Rizzo G; Valente M; Lumachi F
Anticancer Res; 2015 Sep; 35(9):4837-9. PubMed ID: 26254375
[TBL] [Abstract][Full Text] [Related]
32. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
33. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
[TBL] [Abstract][Full Text] [Related]
34. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
[TBL] [Abstract][Full Text] [Related]
35. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
36. F-18 FDG PET/CT findings in two patients with pyothorax-associated lymphoma.
Ito K; Kubota K; Morooka M; Aruga T; Mochizuki N; Itami J; Matsuda H
Clin Nucl Med; 2010 Oct; 35(10):802-5. PubMed ID: 20838292
[TBL] [Abstract][Full Text] [Related]
37. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
39. Lymphoma and Lactic Acidosis.
McKay JW; Delbeke D; Sandler MP
Clin Nucl Med; 2017 May; 42(5):371-372. PubMed ID: 28221192
[TBL] [Abstract][Full Text] [Related]
40. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
